NCT06747858Phase 2Recruiting

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Study sponsor: Arcturus Therapeutics, Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-06Estimated

Enrollment · participants33Estimated

Source updated2026-05-08Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-05-08 · 2 fields changed

Planned enrollment increased by 21 participants

− Before

~~12 participants (planned)~~

+ After

33 participants (planned)

Primary completion date changed

− Before

~~Dec 2025~~

+ After

Jun 2027

Check registry source